Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection

Recent Patents on Anti-Infective Drug Discovery

Volumn 8, Issue 3, 2013, Pages 213-218

  Taha, Huda ^a   Morgan, James ^a   Das, Archik ^b   Das, Satyajit ^a  

^a University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

GSK 744; HIV; Nanotechnology; Parenteral; Patent drug; Pre exposure prophylaxis

Indexed keywords

CABOTEGRAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; PLACEBO; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; TENOFOVIR DISOPROXIL; DELAYED RELEASE FORMULATION; INTEGRASE INHIBITOR; PYRIDONE DERIVATIVE; SUSPENSION;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); NANOTECHNOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS REPLICATION; DELAYED RELEASE FORMULATION; HIV INFECTIONS; PATENT; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; SUSPENSION;

DELAYED-ACTION PREPARATIONS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; NANOTECHNOLOGY; PATENTS AS TOPIC; PRE-EXPOSURE PROPHYLAXIS; PYRIDONES; SUSPENSIONS;

EID: 84901816437     PISSN: 1574891X     EISSN: 22124071     Source Type: Journal    
DOI: 10.2174/1574891X09666140417154727     Document Type: Article

References (47)

1. Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med 2013; 64: 219-32.
2. Curran K, Baeten JM, Coates TJ, Kuth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep 2012; 9(2): 160-70.
3. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, Van den Ooord J, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10(4): 379-89.
4. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, et al. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: A mathematical modelling study. PLoS Med 2012; 9(10): e1001323.
5. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4(151): 151ra125.
6. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis 2011; 25(1): 51-7.
7. Celum C, Baeten JM. Antiretroviral-based HIV-1 prevention: Antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther 2011; 17(8): 1483-93.
8. Celum C. HIV preexposure prophylaxis: New data and potential use. Topics in antiviral medicine 2011; 19(5): 181-5.
9. Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26(7): F13-9.
10. Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis 2011; 32(1): 1-8.
11. Blumenthal PF, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: Increasing use of long-acting reversible contraception. Hum Reprod Update 2010; 17(1): 121-37.
12. Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res 2012; 96(3): 430-6.
13. Uckun FM, Cahn P, Qazi S, D'Cruz O. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin Investig Drugs 2012; 21(4): 489-500.
14. Lisziewicz J, Toke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine: Nanotechnology, Biology, and Medicine 2013; 9(1): 28-38.
15. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv 2010; 7(1): 37-48.
16. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8(6): 565-71.
17. Ham AS, Cost MR, Sassi AB, Dezutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 2009; 26(3): 502-11.
18. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001; 47(1): 39-54.
19. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed 2010; 5: 533-47.
20. Andrews C, Gettie A, Russell-Lodrigue K, et al. Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV. Proceedings of the 20th Conference on Retroviruses and Opportinistic Infection. Atlanta, USA, March 3-6, 2013.
21. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, et al. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine 2012; 7(8): 1253-71.
22. Cohen MS, Kaleebu P, Coates T. Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc 2008; 11: 4.
23. Hellinger FJ. Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. Pharmaco Econ 2013; 31(12): 1091-104.
24. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-74.
25. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med 2012; 367(5): 423-34.
26. Vacca, J., Wai, J.S., Payne, L.S., Isaccs, R.C.A., Han, W., Egbertson, M., et al. HIV Integrase inhibitors. US2013178468 (2013).
27. Koh Y, Haim H, Engelman A. Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. Antimicrob Agents Chemother 2010; 55(1): 42-9.
28. Johns BA, Boros E, Kawasuji T, Koble C, Kurose N, Murai H, et al. HIV integrase inhibitors. EP1720856B1 (2013).
29. Chen Q, Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, et al. Impact of resistance mutations on inhibitor binding to HIV-1 Integrase. J Chem Inf Modeling 2013; 53(12): 3297-307.
30. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIVAIDS infection. J Med Chem 2008; 51(18): 5843-55.
31. Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: Final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13(7): 587-96.
32. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2012; 207(5): 740-8.
33. Marchand C. The elvitegravir Quad pill: The first once-daily dualtarget anti-HIV tablet. Expert Opin Invest Drugs 2012; 21(7): 901-4.
34. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7(5): 390-400.
35. Boyd M. Dolutegravir--a promising antiretroviral in development. Lancet Infect Dis 2012; 12(2): 90-1.
36. Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother 2013; 68(11): 2525-32
37. Lou S, Gould E, Chen S, Wilfret D, Spreen W, Piscitelli S, et al. Meta-Analysis of safety data from eight clinical studies with GSK1265744, an HIV integrase inhibitor, dosed orally or as injection of long-acting parenteral nanosuspension. Proceedings of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). Denver, USA, September 10-13, 2013.
38. Spreen W, Margolis PWD, Ford S, Crauwels H, Lou Y, Gould E, et al. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: Pharmacokinetics, safety and tolerability in healthy adults. Proceedings of the 7th IAS conference on HIV pathogenesis, treatment and prevention. Kuala Lumpur, Malyasia, June 30-July 3, 2013.
39. Jackson A, Else L, Tjia J, Seymour M, Back D, Gazzard B, et al. Rilpivirine-LA formulation: Pharmacokinetics in plasma, genital tract in HIV-females and rectum in males. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, March 5-8, 2012.
40. Ford S, Margolis D, Chen S, Gould E, Spreen W. Plasma and tissue GSK1265744 pharmacokinetics following long-acting parenteral administration in healthy male and female subjects. Proceedings of the 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, Netherlands, April 22-24, 2013.
41. Ford S, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and the integrase inhibitors dolutegravir and S/GSK 1265744. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, September 9-12, 2012.
42. Yoshinaga T, Kobayashi M, Seki T, Kawasuji T, Taishi T, Sato A, et al. Antiviral characteristics of S/GSK1265744, an HIV integrase inhibitor (INI) dosed by oral or long-acting parenteral injection... once monthly or 3 months dosing/PrEP/HAART. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, September 9-12, 2012.
43. Karmon SL, Markowitz M. Next-generation integrase inhibitors: Where to after raltegravir?. Drugs 2013; 73(3): 213-28.
44. Smith J, Rastogi R, Teller R, Srinivasan P, Pau C-P, McNicholl J, et al. A novel intravaginal ring design releasing tenofovir delivers comparable tenofovir diphosphate levels in vaginal target cells in macaques to gel dosing. Proceedings of the 20th Conference on Retroviruses and Opportinistic Infection. Atlanta, USA, March 3-6, 2013.
45. Spreen W, Ford SL, Chen S, Gould E, Wilfret D, Subich D, et al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor S/GSK1265744 long acting parenteral nanosuspension following single dose administration to healthy adults. Proceedings of the XIX International AIDS Conference. Washington, USA, July 22-27, 2012.
46. FDA Grants Priority Review Designation for ViiV's Dolutegravir. Available at: http://www.aidsmeds.com/articles/dolutegravir_priority_1667_234 80.shtml (Accessed on: February 16, 2014)
47. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381(9883): 2083-90.